ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AADI Aadi Bioscience Inc

1.60
0.00 (0.00%)
Pre Market
Last Updated: 12:00:01
Delayed by 15 minutes
Share Name Share Symbol Market Type
Aadi Bioscience Inc NASDAQ:AADI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.60 1.57 1.69 0 12:00:01

Aadi Bioscience to Participate at Upcoming Investor Conferences

05/09/2023 1:00pm

PR Newswire (US)


Aadi Bioscience (NASDAQ:AADI)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more Aadi Bioscience Charts.

LOS ANGELES, Sept. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with mTOR pathway alterations, announced today participation at the following investor events:

  • H.C. Wainwright 25th Annual Global Investment Conference - The conference will take place September 11-13, 2023, in both a virtual and in-person format in New York City.  Scott Giacobello, Interim CEO and President and CFO of Aadi, will present in-person on Tuesday, September 12, 2023, at 12:00 pm ET
  • Morgan Stanley 21st Annual Global Healthcare Conference – The conference will take place September 11-13, 2023, in New York City.  Mr. Giacobello will participate in an in-person fireside chat on Wednesday, September 13, 2023, at 9:30 am ET

The presentation and fireside chat will be webcast live on the IR pages of the Aadi Bioscience website and will be available for replay for approximately 30 days following each investor event.

About Aadi Bioscience, Inc.
Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Aadi received FDA approval in November 2021, and in February 2022 commenced commercialization of FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi is conducting the PRECISION1 trial, a Phase 2 tumor-agnostic registration-directed study in patients with mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on Aadi's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:
Marcy Graham
IR@aadibio.com 

(PRNewsfoto/Aadi Bioscience)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-participate-at-upcoming-investor-conferences-301917694.html

SOURCE Aadi Bioscience

Copyright 2023 PR Newswire

1 Year Aadi Bioscience Chart

1 Year Aadi Bioscience Chart

1 Month Aadi Bioscience Chart

1 Month Aadi Bioscience Chart

Your Recent History

Delayed Upgrade Clock